Human immunodeficiency virus (HIV) attacks the immune system of the individual. The human immunodeficiency virus (HIV) is a type of retrovirus that causes acquired immunodeficiency syndrome (AIDS). AIDS refers to a set of symptoms and illnesses. It is one of the most widespread and incurable deficiency syndromes among humans across the world. HIV spreads through unprotected intercourse with a person infected with HIV. HIV can also be transmitted through transfusion of contaminated blood, from infected mother to child during breastfeeding and pregnancy, and due to sharing of contaminated needles and syringes. Some of the symptoms of HIV infection are swollen glands, headache, slight fever, fatigue, and muscle ache. At present, HIV infection can be treated by drugs that belong to classes such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry and fusion inhibitors, integrase inhibitors, and protease inhibitors (PIs). Truvada, Atripla, Stribild, and Prezista/Prezcobix are some of the key drugs available in the market for treating HIV/AIDS.
According to a WHO report, by the end of 2015, the number of people infected by HIV, globally, stood at 36.7 million. The global HIV/AIDS drugs market is expanding significantly due to increasing prevalence of the disease. Rise in the incidence of unprotected sex has led to increase in the prevalence of HIV/AIDS. Increase in funding from government and private sectors for the treatment of HIV/AIDS in terms of reimbursement is projected to drive the market during the forecast period. Low rate of voluntary screening for the disease is a major restraint for the market. Awareness about diagnostic tests for HIV infection is extremely low in countries in Africa. Hence, companies are facing challenges in penetrating the market in the region. Moreover, several low- and middle-income countries depend on government grants for provision of rapid diagnostic tests in the event of an epidemic. Therefore, their direct reach to customers is weak in these countries. These factors hamper the market in the region.
The global HIV/AIDS drugs market can be segmented based on drug class, distribution channel, and region. In terms of drug class, the market can be categorized into nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry & fusion inhibitors, integrase inhibitors, protease inhibitors (PIs), and combination class drugs. In terms of revenue, the combination class drugs segment held a significant share of the HIV/AIDS drug market in 2016. Atripla, Triumeq, and Truvada held a significant share of the market in 2016. In terms of distribution channel, the global HIV/AIDS drugs market can be classified into hospital pharmacies, retail pharmacies, online pharmacies, and others. In terms of revenue, the hospital pharmacies segment held a significant share of the HIV/AIDS drugs market in 2016.
In terms of region, the global HIV/AIDS drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the leading market for HIV/AIDS drugs. In terms of revenue, the U.S. holds a major share of the HIV/AIDS drugs market in North America. The market in Europe is expanding rapidly due to increase in the patient population in the region, especially in the U.K. and Germany. The market in Asia Pacific and Latin America is projected to expand significantly in the near future. Developing economies such as China and India are anticipated to contribute to growth of the market in Asia Pacific between 2017 and 2025, due to better health care infrastructure, economic growth, increase in the number of insurance payers, growth of the private health care sector, and increase in awareness among people in these countries.
Key players operating in the global HIV/AIDS drugs market are Gilead Sciences, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Johnson & Johnson, Bristol-Myers Squibb Co., AbbVie Inc., Pfizer, Inc., Alexion Pharmaceuticals, and Shionogi.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.